KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Retained Earnings (2016 - 2026)

Palvella Therapeutics has reported Retained Earnings over the past 10 years, most recently at -$254000.0 for Q4 2022.

  • Quarterly Retained Earnings fell 130.64% to -$254000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$254000.0 through Dec 2022, down 130.64% year-over-year, with the annual reading at -$254000.0 for FY2022, 130.64% down from the prior year.
  • Retained Earnings was -$254000.0 for Q4 2022 at Palvella Therapeutics, down from $524000.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $829000.0 in Q4 2021 and troughed at -$272.6 million in Q2 2022.
  • The 5-year median for Retained Earnings is -$138.1 million (2018), against an average of -$109.2 million.
  • Year-over-year, Retained Earnings crashed 28164.85% in 2020 and then soared 100.39% in 2021.
  • A 5-year view of Retained Earnings shows it stood at -$147.1 million in 2018, then soared by 98.64% to -$2.0 million in 2019, then tumbled by 10496.79% to -$211.4 million in 2020, then soared by 100.39% to $829000.0 in 2021, then plummeted by 130.64% to -$254000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Retained Earnings are -$254000.0 (Q4 2022), $524000.0 (Q3 2022), and -$272.6 million (Q2 2022).